英国的一项试验测试将化疗和VP-002相结合的一种新的胰腺癌治疗,以减少副作用和改善结果。 A UK trial tests a new pancreatic cancer treatment combining chemo with VP-002 to reduce side effects and improve outcomes.

联合王国在Addenbrooke医院进行的一项试验正在测试第4阶段胰腺癌的新治疗方法,将标准化疗与VP-002相结合,VP-002是一种针对CCR1受体的药物,以削弱肿瘤和减少治疗耐药性。 A UK trial at Addenbrooke’s Hospital is testing a new treatment for stage 4 pancreatic cancer, combining standard chemotherapy with VP-002, a drug targeting the CCR1 receptor to weaken tumors and reduce treatment resistance. CRISTAL-APC研究涉及15所医院120名病人,旨在降低化疗剂量和副作用,同时保持有效性。 The CRISTAL-APC study, involving 120 patients across 15 hospitals, aims to lower chemotherapy doses and side effects while maintaining effectiveness. 它由Bristi Basu博士领导,它包括病人的投入,例如幸存者Sally Pascall的投入,将生活质量列为优先事项。 Led by Dr. Bristi Basu, it includes patient input, such as from survivor Sally Pascall, to prioritize quality of life. 这次试验在世界泛岛癌症日上得到强调,它为一种治疗选择有限的疾病带来了希望,在联合王国每年影响约10,000人。 The trial, highlighted on World Pancreatic Cancer Day, offers hope for a disease with limited treatment options, affecting about 10,000 people annually in the UK.